Aurobindo Pharma received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Perampanel Tablets in six strengths: 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. These tablets are indicated for treating partial-onset seizures and primary generalized tonic-clonic seizures in patients with epilepsy.

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Fycompa® Tablets, marketed by Catalyst Pharmaceuticals, Inc. The launch is scheduled for Q3FY27, positioning the company to capture a share of the established US generic market for this anti-epileptic drug.

Market opportunity and regulatory status

The USFDA approval adds to Aurobindo’s growing portfolio of regulated products. The company will manufacture the tablets at Unit-IV of APL Healthcare, a wholly owned subsidiary. This facility expansion underscores the firm's strategy to deepen its presence in the Central Nervous System (CNS) therapeutic segment, which is one of its seven major product areas.

What the numbers show

The commercial potential of the new approval is anchored in the existing demand for the reference drug. According to IQVIA MAT data, the estimated market size for the reference listed drug was $67 million for the twelve months ending August 2026. This figure represents the total addressable market that the generic entry can now compete for, subject to pricing dynamics and competitor responses.

The approval brings Aurobindo Pharma’s total count of ANDA approvals from the USFDA to 599. Of these, 574 are final approvals and 25 are tentative. This high volume of final approvals indicates a robust pipeline conversion rate, where a significant majority of filed applications have successfully cleared regulatory hurdles to reach the final marketing stage.

Product indications

Perampanel Tablets are prescribed for two specific conditions in patients with epilepsy:

• Treatment of partial-onset seizures, with or without secondarily generalized seizures, in patients aged 4 years and older.
• Adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 12 years and older.

Aurobindo Pharma Limited has expanded its contract research footprint in the United States. Its wholly owned subsidiary Apitoria Pharma Private Limited, through its US entity A1 Biochem USA Inc, completed the acquisition of A1 Biochem Labs LLC on October 2, 2026.

The transaction involves a cash consideration of $15.247 million for 100% membership interest in the target. This move complements the earlier acquisition of A1 Biochem Labs (India) Private Limited, where former promoter Dr. Rajendra Gadikota retained a 20% stake. The combined entities now form a dedicated Contract Research, Development and Manufacturing (CRDMO) platform, aligning with the company’s strategic objective to expand presence in the Active Pharmaceutical Ingredients (API) business lifecycle.

Acquisition Details and Financials

A1 Biochem Labs LLC operates from Wilmington, North Carolina, providing contract research, custom synthesis, and medicinal chemistry services. The entity was incorporated in September 2015 and is led by Dr. Gadikota, who has over 25 years of experience in the sector and will continue employment post-acquisition.

The financial performance of the acquired unit shows fluctuation in recent years:

Note: Data for calendar year ending December 31, 2025, is reported as USD 5.92 Million in the disclosure.

The acquisition was completed subject to customary conditions under definitive agreements entered into on July 23, 2026. No governmental or regulatory approvals were required for this specific transaction.

Strategic Rationale and Structure

This acquisition integrates front-end research and development capabilities with Apitoria’s existing large-scale API manufacturing operations. By combining these functions, Aurobindo aims to offer full-service engagement to customers, facilitating longer lifecycle interactions. The transaction is described as complementary to the current API manufacturing business of Apitoria and A1 Labs India.

Structurally, A1 Biochem USA Inc, a wholly owned subsidiary of A1 Biochem Labs (India) Private Limited, acquired the US entity. Consequently, A1 Labs LLC becomes a step-down subsidiary of the Indian entity. The disclosure notes that Dr. Gadikota serves as a director of A1 Labs India, making this a related party transaction conducted at arm’s length. However, the promoter group of Aurobindo Pharma holds no interest in the target entity.

Integration with Previous Stakeholding Agreement

This development follows the completion of the acquisition of A1 Biochem Labs (India) Private Limited. In that earlier deal, Dr. Gadikota subscribed to a 20% stake in the Indian entity on a fully diluted basis. He purchased 89,94,500 equity shares and 2,41,05,500 Compulsory Convertible Debentures (CCDs) on September 30, 2026.

Apitoria retains an 80% holding in the Indian entity and holds an option to acquire the remaining 20% stake in the future. Since A1 Biochem Labs (India) was acquired in July 2026, it did not contribute to revenue or net worth as on March 31, 2026.

Expanded Client Base and Project Portfolio

Through this acquisition, Apitoria now has access to an existing Contract Research Organization (CRO) platform with a client base of 50+ and experience completing 800+ projects across India and the USA. This addition complements Apitoria's manufacturing capabilities to create an integrated CRDMO platform. The expanded portfolio of offerings is intended to facilitate longer life cycle engagement with customers.

What the Numbers Show

The acquisition price of $15.247 million represents approximately 1.6 times the peak annual sales recorded by A1 Labs LLC ($9.23 million in calendar year 2024). However, against the most recent reported sales of $5.92 million (calendar year 2025), the valuation implies a multiple of roughly 2.6 times. This divergence suggests the company may be pricing in future recovery or synergies from integrating the research unit with its manufacturing base, rather than valuing solely on trailing current-year revenue. The shift from equity-heavy structures in the Indian entity to a cash-based acquisition for the US asset highlights different capital allocation strategies for distinct geographic assets.